arrow
L

Laura L. Michel

german cancer research center—dkfz
H指数:14
被引数:1,118

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Comprehensive Liquid Biopsy Testing in Metastatic Hormone Receptor-Positive HER2-Negative Breast Cancer Patients: First Results from Routine Clinical Practice

转移性激素受体阳性HER2阴性乳腺癌患者中的全面液体活检检测:来自常规临床实践的首批结果

2026-05-010
PRE
Alpelisib and Fulvestrant in PIK3CA-mutated hormone receptor-positive HER2-negative advanced breast cancer included in the German PRAEGNANT trial

Alpelisib和Fulvestrant在德国PRAEGNANT试验中纳入的PIK3CA突变的激素受体阳性HER2阴性晚期乳腺癌

2026-04-020
OAAI
Delivering precision oncology in metastatic breast cancer: Clinical impact of comprehensive genomic profiling—The CATCH experience

在转移性乳腺癌中实施精准肿瘤学:全面基因组分析的临床影响——CATCH研究经验

2025-10-310
OAAI
Fast enrichment and detection of circulating tumor cells from large volumes of whole blood of breast cancer patients utilizing a functionalized bioaffinity CTC filtration membrane

利用功能化生物亲和性CTC过滤膜,快速富集和检测来自乳腺癌患者大量全血中的循环肿瘤细胞

2025-10-270
OAAI
P11.37.B NOVEL PATIENT-DERIVED BREAST CANCER BRAIN METASTASES MODELS CHARACTERIZED BY LARGE-SCALE DRUG SCREENING AND INTEGRATIVE MULTI-OMICS PROFILING

P11.37.B 基于患者来源的乳腺癌脑转移瘤新型模型,通过大规模药物筛选和整合多组学分析进行表征

2025-10-030
OA
Overall Survival in Metastatic Breast Cancer Patients: Real-World Data from 1,000 Patients Treated at the NCT Heidelberg between 2014 and 2022

转移性乳腺癌患者总生存期:来自NCT海德堡2014年至2022年间治疗的1,000例患者的真实世界数据

2025-10-010
PRE
Prognostic impact of the choice of chemotherapy after first-line CDK4/6 inhibitor therapy in patients with metastatic hormone receptor-positive, HER2-negative breast cancer

在接受一线CDK4/6抑制剂治疗后,转移性激素受体阳性、HER2阴性乳腺癌患者选择化疗方案的预后影响

2025-08-050
OA
Efficacy of Hand Cooling and Compression in Preventing Taxane-Induced Neuropathy The POLAR Randomized Clinical Trial

手部冷却和加压在预防紫杉烷类诱导神经病变中的疗效:POLAR随机临床试验

2025-04-010
PRE
Characteristics and prognosis of patients with primary metastatic disease vs. recurrent HER2-negative, hormone receptor-positive advanced breast cancer

原发转移性疾病与复发HER2-negative、激素受体阳性晚期乳腺癌患者的特征及预后比较

BREAST
IF7.9
2025-04-010
OAAI
Small extracellular vesicles and particles (sEVPs) derived from tumor-free pre-metastatic organs promote breast cancer metastasis and support organotropism

来自无肿瘤的转移前器官的微小细胞外囊泡和颗粒(sEVPs)促进乳腺癌转移并支持器官特异性转移

2025-03-081
OA
Isolation of a tumor neoantigen specific CD8+TCR from a skin biopsy of a vaccination site

从疫苗接种部位的皮肤活检中分离出肿瘤新抗原特异性CD8 TCR

2025-02-040
OA
Biopsy-derived organoids in personalised early breast cancer care: Challenges of tumour purity and normal cell overgrowth cap their practical utility
2025-02-010
OAAI
Discovery of a sushi domain-containing protein 2-positive phenotype in circulating tumor cells of metastatic breast cancer patients
2025-01-310
OAAI
The impact of physical activity on progression-free and overall survival in metastatic breast cancer based on molecular subtype
2024-10-162
OAAI
Neoadjuvant chemotherapy in inflammatory breast cancer: A meta-analysis of 10 trials of the German Breast Group (GBG)

炎性乳腺癌的新辅助化疗:德国乳腺癌组(GBG)10项试验的Meta分析

2024-09-010
PRE
COGNITION/-GUIDE - Implementation of Precision Oncology in Early High-Risk Breast Cancer
2024-05-020
PRE
Detection and Isolation of Circulating Tumor Cells from Breast Cancer Patients Using CUB Domain-Containing Protein 1
2023-03-168
PRE
Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: Pharmacokinetic, safety and patients' preference-Substudy of the randomised phase III GAIN-2 study
BREAST
IF7.9
2022-12-013
OAAI